Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director | August 11, 2026 | August 12, 2026 |
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | Director | May 05, 2026 | May 07, 2026 |
| ChronoScale Holdings CorpEKSO · Entity 4331 | Director | September 14, 2017 | September 15, 2017 |
| Solventum CorpSOLV · Entity 1645 | Director | May 15, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,976 |
Ending reported balance
After 2026-08-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-11 · Exercise / conversion · Acquired 13,353 · Balance 121,329 Row 2 · 2026-08-11 · Sale · Disposed 13,353 · Balance 107,976 F1: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2026. F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.82 to $49.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $14.85 · Expires 2027-06-01 | Direct | 0 |
Reported balance
After 2026-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-11 · Exercise / conversion · Disposed 13,353 · Balance 0 F3: All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 14, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2026.
F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.82 to $49.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3: All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 14, 2018.
BAXTER INTERNATIONAL INC
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 44,235 |
Reported balance
After 2026-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-05 · Grant · Acquired 12,836 · Balance 44,235 F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2: Total includes the automatic reinvestment of dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.
F2: Total includes the automatic reinvestment of dividends.
ChronoScale Holdings Corp
Report date September 14, 2017 · Filed September 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,264 |
Reported balance
After 2017-09-14 transaction · row 1
1 source rowRow 1 · 2017-09-14 · Purchase · Acquired 16,264 · Balance 16,264 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.24, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.24, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Solventum Corp
Report date May 15, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,300 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 3,300 · Balance 3,300 F1: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
F2: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HOLOGIC INC
Report date April 07, 2026 · Filed April 09, 2026
Section 16 reporting ended · disclosed 2026-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Disposition to issuer · Disposed 25,784 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.79 · Expires 2026-12-14 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-07 · Disposition to issuer · Disposed 1,500 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.92 · Expires 2027-03-08 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Disposition to issuer · Disposed 6,816 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.44 · Expires 2028-03-14 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-07 · Disposition to issuer · Disposed 7,551 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.81 · Expires 2029-03-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-07 · Disposition to issuer · Disposed 6,523 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.36 · Expires 2030-03-05 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-07 · Disposition to issuer · Disposed 7,322 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.03 · Expires 2031-03-11 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-07 · Disposition to issuer · Disposed 5,055 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.28 · Expires 2032-03-10 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-07 · Disposition to issuer · Disposed 5,293 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.49 · Expires 2033-03-09 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-07 · Disposition to issuer · Disposed 4,210 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.32 · Expires 2034-03-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-07 · Disposition to issuer · Disposed 4,536 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.36 · Expires 2035-02-26 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-04-07 · Disposition to issuer · Disposed 5,535 · Balance 0 F3: For Footnote (3), see Remarks below. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").
F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F3: For Footnote (3), see Remarks below.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 12, 2026 20:12 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 13,353 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0000805928-26-000098 · wk-form4_1786565567.xml · derivative · entry 3 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,353 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 14, 2018. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 20:12 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 13,353 | $48.42 | $646,592.32 |
DisclosureSEC source: 0000805928-26-000098 · wk-form4_1786565567.xml · nonDerivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,976 F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2026. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.82 to $49.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 20:12 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 13,353 | $14.85 | $198,292.05 |
DisclosureSEC source: 0000805928-26-000098 · wk-form4_1786565567.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:52 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 4,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001400568-26-000015 · wk-form4_1782507140.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,392 Underlying: Common Stock · 4,392 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date. F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date. Read SEC document |
| June 19, 2026 Filed Jun 23, 2026 20:36 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 14,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001400568-26-000013 · wk-form4_1782246998.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. Read SEC document |
| June 19, 2026 Filed Jun 23, 2026 20:36 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 14,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001400568-26-000013 · wk-form4_1782246998.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026. Read SEC document |
| May 15, 2026 Filed May 18, 2026 21:35 UTC | Solventum Corp SOLV · Entity 1645 | GrantRestricted Stock Units · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001400568-26-000011 · wk-form4_1779140149.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,300 Underlying: Common Stock · 3,300 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date. F2 · derivative.expiration_date: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date. Read SEC document |
| May 08, 2026 Filed May 12, 2026 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 1,647 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001400568-26-000009 · wk-form4_1778616387.xml · derivative · entry 3 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,353 Underlying: Common Stock · 1,647 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 31, 2018. Read SEC document |
| May 08, 2026 Filed May 12, 2026 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 1,647 | $42.60 | $70,162.20 |
DisclosureSEC source: 0001400568-26-000009 · wk-form4_1778616387.xml · nonDerivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,826 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.50 to $42.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2026 Filed May 12, 2026 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 1,647 | $14.85 | $24,457.95 |
DisclosureSEC source: 0001400568-26-000009 · wk-form4_1778616387.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:21 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 12,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032190 · wk-form4_1778185265.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,235 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:31 UTC | Solventum Corp SOLV · Entity 1645 | Exercise / conversionRestricted Stock Units · Derivative | 3,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001400568-26-000007 · wk-form4_1777667475.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,403 shares Expires 2035-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs are fully vested. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:31 UTC | Solventum Corp SOLV · Entity 1645 | Exercise / conversionCommon Stock | 3,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001400568-26-000007 · wk-form4_1777667475.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,535 | Not disclosed Strike: $64.36 | Not disclosed |
DisclosureSEC source: 0000859737-26-000077 · form4.xml · derivative · entry 11 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,535 shares Expires 2035-02-26 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 4,536 | Not disclosed Strike: $76.32 | Not disclosed |
DisclosureSEC source: 0000859737-26-000077 · form4.xml · derivative · entry 10 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,536 shares Expires 2034-03-07 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 4,210 | Not disclosed Strike: $78.49 | Not disclosed |
DisclosureSEC source: 0000859737-26-000077 · form4.xml · derivative · entry 9 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,210 shares Expires 2033-03-09 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,293 | Not disclosed Strike: $70.28 | Not disclosed |
DisclosureSEC source: 0000859737-26-000077 · form4.xml · derivative · entry 8 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,293 shares Expires 2032-03-10 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,055 | Not disclosed Strike: $71.03 | Not disclosed |
DisclosureSEC source: 0000859737-26-000077 · form4.xml · derivative · entry 7 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,055 shares Expires 2031-03-11 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 7,322 | Not disclosed Strike: $47.36 | Not disclosed |
DisclosureSEC source: 0000859737-26-000077 · form4.xml · derivative · entry 6 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,322 shares Expires 2030-03-05 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 6,523 | Not disclosed Strike: $46.81 | Not disclosed |
DisclosureSEC source: 0000859737-26-000077 · form4.xml · derivative · entry 5 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,523 shares Expires 2029-03-07 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 7,551 | Not disclosed Strike: $38.44 | Not disclosed |
DisclosureSEC source: 0000859737-26-000077 · form4.xml · derivative · entry 4 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,551 shares Expires 2028-03-14 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 6,816 | Not disclosed Strike: $41.92 | Not disclosed |
DisclosureSEC source: 0000859737-26-000077 · form4.xml · derivative · entry 3 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,816 shares Expires 2027-03-08 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 1,500 | Not disclosed Strike: $40.79 | Not disclosed |
DisclosureSEC source: 0000859737-26-000077 · form4.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2026-12-14 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerCommon Stock | 25,784 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000077 · form4.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2 · price: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. Read SEC document |
| March 27, 2026 Filed Mar 30, 2026 23:38 UTC | Solventum Corp SOLV · Entity 1645 | Exercise / conversionRestricted Stock Units · Derivative | 1,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001400568-26-000004 · wk-form4_1774913889.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,980 shares Expires 2034-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs are fully vested. Read SEC document |
| March 27, 2026 Filed Mar 30, 2026 23:38 UTC | Solventum Corp SOLV · Entity 1645 | Exercise / conversionCommon Stock | 1,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001400568-26-000004 · wk-form4_1774913889.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 10:31 UTC | Solventum Corp SOLV · Entity 1645 | PurchaseCommon Stock | 1,475 | $68.03 | $100,344.25 |
DisclosureSEC source: 0001400568-26-000002 · wk-form4_1773225067.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,039 Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 3,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000031 · form4.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,784 F1 · shares: Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 18,248 | $0.00 Strike: $7.04 | $0.00 |
DisclosureSEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · derivative · entry 9 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,248 shares Expires 2034-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Board of Directors' non-qualified stock option grant that vested in full June 6, 2025. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · derivative · entry 8 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Board of Directors' non-qualified stock option grant that vested in full September 1, 2024. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 5,000 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · derivative · entry 7 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2026-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Board of Directors' non-qualified stock option grant that vested in full May 26, 2017. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:25 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 18,248 | $29.31 | $534,885.38 |
DisclosureSEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · nonDerivative · entry 6 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,826 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.99 to $29.63 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:25 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 20,436 | $29.31 | $599,020.03 |
DisclosureSEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · nonDerivative · entry 5 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,074 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.99 to $29.63 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:25 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 5,000 | $29.31 | $146,560.00 |
DisclosureSEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · nonDerivative · entry 4 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,510 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.99 to $29.63 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 18,248 | $7.04 | $128,465.92 |
DisclosureSEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · nonDerivative · entry 3 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 20,436 | $6.30 | $128,746.80 |
DisclosureSEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · nonDerivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 21:25 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 5,000 | $8.95 | $44,750.00 |
DisclosureSEC source: 0001400568-25-000005 · wk-form4_1766006718.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2025 Filed Jun 20, 2025 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 14,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000100 · wk-form4_1750450184.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,150 Underlying: Common Stock · 14,150 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:26 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 4,073 | $10.61 | $43,214.53 |
DisclosureSEC source: 0000805928-25-000084 · wk-form4_1749673557.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,826 F1 · shares: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:22 UTC | Solventum Corp SOLV · Entity 1645 | Exercise / conversionRestricted Stock Units · Derivative | 3,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-025956 · wk-form4_1747340508.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,564 shares Expires 2034-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs fully vested on May 13, 2025. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:22 UTC | Solventum Corp SOLV · Entity 1645 | Exercise / conversionCommon Stock | 3,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-025956 · wk-form4_1747340508.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2025 Filed May 8, 2025 20:28 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 7,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-008904 · form4.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,222 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:16 UTC | Solventum Corp SOLV · Entity 1645 | GrantRestricted Stock Units · Derivative | 3,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-021842 · wk-form4_1746216974.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,403 Underlying: Common Stock · 3,403 shares Expires 2025-04-30 F1 · derivative.exercise_price: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs shall fully vest on April 30, 2026, subject to continued service through the vesting date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 23:20 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 5,000 | $20.02 | $100,100.00 |
DisclosureSEC source: 0000805928-25-000034 · wk-form4_1741216805.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,899 F1 · shares: The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan, as defined under the Company's Insider Trading Policy. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $19.91 to $20.15 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,535 | $0.00 Strike: $64.36 | $0.00 |
DisclosureSEC source: 0001127602-25-007276 · form4.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,535 Underlying: Common Stock · 5,535 shares Expires 2035-02-26 F3 · derivative.exercise_date: Options become exercisable on the date of the 2026 Annual Meeting of Stockholders. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:29 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-007276 · form4.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,594 F1 · shares: Represents restricted stock units which vest on the date of the 2026 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 21:18 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000114 · wk-form4_1725482772.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 21:18 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000114 · wk-form4_1725482772.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:24 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 18,248 | $0.00 Strike: $7.04 | $0.00 |
DisclosureSEC source: 0000805928-24-000103 · wk-form4_1718058239.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,248 Underlying: Common Stock · 18,248 shares Expires 2034-06-06 F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year from the anniversary of the grant date. One-half of the annual equity grant is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:24 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 10,653 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000805928-24-000103 · wk-form4_1718058239.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,995 F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.